What Omada Health's latest 10-Q says: 5 signals
Omada Health filed its latest 10-Q with the SEC on Aug 7, 2026. It discusses debt refinancing, digital transformation and margin pressure.
Public (OMDA)Hospitals and Health Care1,001 to 5,000 employeesomadahealth.comLinkedIn
- Filed
- Aug 7, 2026
- Filings
- 2
- Signals
- 9
10-Q · latest 8
What Omada Health's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 5 signals
Omada Health leveraging $151.6M IPO proceeds for platform expansion with AI and data analytics.
With a confirmed $151.6M in capital from its 2025 IPO, Omada is focused on innovating and expanding its platform using data analytics and artificial intelligence.
$151.6M
IPO proceeds available for investment
data analyticsartificial intelligence
Retains significant capital from $151.6M IPO for strategic investments.
After raising $151.6 million from its June 2025 IPO and repaying some debt, Omada Health has a substantial cash reserve for strategic initiatives.
$151.6M
net proceeds from IPO
Morgan Stanley & Co, LLCGoldman Sachs & Co. LLCJ.P. Morgan Securities LLC
Facing increased collection costs and reduced revenue from patient cost-sharing.
The company is struggling to collect payments like co-pays and deductibles from its physical therapy members, which increases operational costs and hurts overall collections.
Omada Health acknowledges that future acquisitions could create risks related to integrating personnel, operations, and intellectual property.
- SEC EDGAR
10-Q
Filed · 4 signals
CFO Steve Cook adopted a Rule 10b5-1 trading plan in March 2026 to sell up to 394,831 shares.
President Wei-Li Shao adopted a Rule 10b5-1 trading plan in March 2026.
Company highlights risk of increased bad debt from uncollected member payments.
Omada is concerned about its inability to collect cost-sharing amounts from members, which could increase accounts receivable write-offs.
Showing 8 of 9 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Omada Health earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Announced major 2026 investment plan in GLP-1 prescribing and AI/GPTs.The CEO has designated 2026 as "the year of the Gs" (GLP-1s and GPTs), signaling significant budget allocation for new product development, engineering, and AI integration to enhance offerings and internal productivity. This creates a prime opportunity for vendors in AI, cloud infrastructure, and product development tools. | |
| Investing in AI to boost internal productivity and drive revenue.The company is actively investing in AI tools to make its care teams more efficient and to enhance product personalization, with the stated goal of increasing both revenue (ARPU) and member retention. This dual focus on cost savings and revenue generation signals a strong business case for AI-related technology and services. | |
| Exploring expansion into the Medicare market following new GLP-1 coverage rules.Following a White House announcement on Medicare coverage for GLP-1s, leadership explicitly stated this could be an expansion opportunity. A potential new market entry is a significant strategic shift that could require new systems, compliance tools, and GTM support tailored to the Medicare population. | |
| Leveraging 'behavioral intelligence' from over 100k usersThe company heavily emphasizes its use of 'behavioral intelligence' derived from health metrics and engagement data. This focus on data-driven insights and real-world evidence suggests an ongoing need for advanced data analytics, processing, and visualization tools. | |
| Demonstrating strong operating leverage and spending disciplineRevenue is growing nearly twice as fast as operating expenses (51% vs 24%), showcasing significant operating leverage. This indicates a focus on efficient, ROI-driven spending, making them a good target for solutions that improve productivity and scalability. | |
| Seeing significant early traction with a new large channel partner, likely CVS.The company has closed multiple launches through a new channel partner, adding an estimated 180,000 individuals, with 75% of these customers adopting multiple Omada programs. An analyst question identified this partner as CVS, indicating a major GTM relationship that may require supporting technology or services to manage. |
Signal API · MCP
Track Omada Health with the Signal API
One POST /v1/companies/enrich call with omadahealth.com returns Omada Health 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"omadahealth.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Omada Health 10-Q
When did Omada Health file its latest 10-Q?
What did Omada Health disclose in its latest 10-Q?
What did Omada Health say on its recent earnings calls?
Where can I read Omada Health's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .